Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.30 |
| ▸ | PRKDC | P78527 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24943794 | 0.87 | RET (0.38) | LRRK2MAPK9MAPK10LCKIRAK4 | |
| SCHEMBL30206248 | 0.85 | LRRK2 (0.37) | LRRK2MAPK9MAPK10IRAK4 | |
| SCHEMBL29173569 | 0.85 | LRRK2 (0.37) | LRRK2MAPK9MAPK10IRAK4 | |
| SCHEMBL24944973 | 0.79 | CCNT1 (0.33) | LRRK2 | |
| SCHEMBL24944164 | 0.76 | RET (0.36) | LRRK2MAPK9MAPK10LCKIRAK4 | |
| SCHEMBL30205760 | 0.75 | EML4 (0.47) | MAPK9MAPK10IRAK4SYK | |
| SCHEMBL24944157 | 0.75 | EML4 (0.47) | MAPK9MAPK10IRAK4SYK | |
| SCHEMBL24944442 | 0.75 | RET (0.37) | LRRK2MAPK9MAPK10LCKIRAK4 | |
| SCHEMBL24944367 | 0.75 | MAPK9 (0.48) | LRRK2MAPK9MAPK10LCKIRAK4 | |
| SCHEMBL30205517 | 0.75 | MAPK9 (0.48) | LRRK2MAPK9MAPK10LCKIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |